Next Article in Journal
Acknowledgement to Reviewers of International Journal of Neonatal Screening in 2019
Next Article in Special Issue
Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I
Previous Article in Journal
Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective
Open AccessArticle

Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction

1
Department of Human Genetics, Emory University, Atlanta, GA 30322, USA
2
Georgia Department of Public Health, Atlanta, GA 30303, USA
3
EGL Genetics, Tucker, GA 30084, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(1), 2; https://doi.org/10.3390/ijns6010002
Received: 16 December 2019 / Revised: 6 January 2020 / Accepted: 10 January 2020 / Published: 14 January 2020
(This article belongs to the Special Issue CLIR Applications for Newborn Screening)
We conducted a pilot newborn screening (NBS) study for Pompe disease (PD) and mucopolysaccharidosis type I (MPS I) in the multiethnic population of Georgia. We screened 59,332 infants using a two-tier strategy of flow injection tandem mass spectrometry (FIA-MSMS) enzyme assays. The first tier of testing was a 2-plex assay measuring PD and MPS I enzyme activity, followed by a second-tier test with additional enzymes to improve specificity. Interpretation of results was performed using post-analytical tools created using Collaborative Laboratory Integrated Reports (CLIR). We identified a single case of infantile onset PD, two cases of late onset PD, and one pseudodeficiency. The positive predictive value (PPV) for PD screening during the study was 66.7%. No cases of MPS I were identified during the study period, but there were 2 confirmed cases of pseudodeficiency and 6 cases lost to follow up. The two-tier screening strategy was successful in reducing false positive results and allowed for the identification and early treatment of a case of infantile PD but the frequency of pseudodeficiency in MPS I is problematic. Molecular testing is required and should be covered by the screening program to avoid delays in case resolution. View Full-Text
Keywords: newborn screening; post-analytical tools; Pompe disease; mucopolysaccharidosis type I; pseudodeficiency newborn screening; post-analytical tools; Pompe disease; mucopolysaccharidosis type I; pseudodeficiency
Show Figures

Figure 1

MDPI and ACS Style

Hall, P.L.; Sanchez, R.; Hagar, A.F.; Jerris, S.C.; Wittenauer, A.; Wilcox, W.R. Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction. Int. J. Neonatal Screen. 2020, 6, 2. https://doi.org/10.3390/ijns6010002

AMA Style

Hall PL, Sanchez R, Hagar AF, Jerris SC, Wittenauer A, Wilcox WR. Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction. International Journal of Neonatal Screening. 2020; 6(1):2. https://doi.org/10.3390/ijns6010002

Chicago/Turabian Style

Hall, Patricia L.; Sanchez, Rossana; Hagar, Arthur F.; Jerris, S. C.; Wittenauer, Angela; Wilcox, William R. 2020. "Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction" Int. J. Neonatal Screen. 6, no. 1: 2. https://doi.org/10.3390/ijns6010002

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop